Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
View Older Stories View More Recent Stories
-
Maxim Group Starts Splunk (SPLK) at Buy
-
Maxim Group Starts Palo Alto Networks (PANW) at Buy
-
Maxim Group Starts Tableau Software (DATA) at Sell
-
The Alliance for Regenerative Medicine Announces Fourth Annual Cell & Gene Therapy Investor Day & Initial Slate of Presenting Companies
-
Inovio (INO) Bullish Stance Reiterated at Maxim Group Amid MERS Trial Patient Recruitment and Zika Vaccine Progress
-
Notable Analyst Rating Changes 1/28: (HAL) (KMI) (NMBL) Upgraded; (ROK) (SEIC) (TRIP) Downgraded
-
Maxim Group Starts Pure Storage (PSTG) at Buy
-
Maxim Group Upgrades Nimble Storage (NMBL) to Buy
-
Paragon Shipping Inc. Reports Third Quarter And Nine Months Ended September 30, 2015 Results
-
Maxim Group Downgrades Engility Holdings, Inc. (EGL) to Hold
-
Maxim Group Starts The Joint Corp (JYNT) at Buy
-
GTX Corp Engages Maxim Group LLC to Provide Strategic Advisory Services
-
Blue Sphere CEO Update Letter
-
Duos Technologies Engages Maxim Group LLC as Corporate Finance Advisor
-
PlacementTracker Publishes 2015 PIPE Market League Tables
-
Epizyme Announces Closing of Public Offering of Common Stock
-
Capnia Closes Second Tranche of Private Placement of Convertible Preferred Stock
-
Maxim Group Positive on Anavex (AVXL) Dose Response Curve
-
Maxim Group Upgrades Momenta Pharmaceuticals (MNTA) to Hold
-
Maxim Group Downgrades AO Smith (AOS) to Hold
-
OTG EXP, Inc. Files Registration Statement for Initial Public Offering of Common Stock
-
Out of flavor: Wall Street slashes targets on Chipotle
-
Streetinsider.com's Hot Lunchtime Reads 1/7: (TSLA) (GSI) (NFLX) (ADTN)
-
Maxim Group Reiterates $5 Price Target on Mast Therapeutics (MSTX)
-
Galena Biopharma (GALE) Prices 19.8M Common Stock and Warrant Offering at $1.10/Unit
-
Galena Biopharma Announces Pricing of Public Offering of Common Stock and Warrants
-
Maxim Group Downgrades Caladrius Biosciences (CLBS) to Hold
-
Epizyme (EPZM) Prices 13.33M Common Offering at $9/Share
-
Epizyme Announces Pricing of Public Offering of Common Stock
-
Apple shares drop below $100 for first time since August
-
The Alliance for Regenerative Medicine Announces 2016 Regen Med and Advanced Therapies State of the Industry Briefing
-
Chipotle hit with U.S. subpoena over California norovirus outbreak
-
Inovio (INO) PT Lowered to $14 at Maxim Group; 'Buy' Maintained
-
bluebird bio (BLUE) PT Cut to $105 at Maxim Group; 'Buy' Maintained
-
The Joint Corp. Announces Exercise of Over-Allotment Option
-
Gilead (GILD) Bullish Stance Reiterated at Maxim Group Following Priority Review for Sofosbuvir in Chronic HCV
-
Benitec BioPharma (BNTC) PT Lowered to $14 at Maxim Group
-
Streetinsider.com's Hot Lunchtime Reads 12/31: (EGY) (SWHC) (AAPL) (VRX)
-
IntelliPharmaCeutics (IPCI) PT Lowered to $6 at Maxim Group
-
Anavex Life Sciences (AVXL) Losses Mount Amid SEC Subpoena, Investigation
-
Mesoblast Limited (MESO) PT More Than Doubled at Maxim Group
-
ContraFect (CFRX) PT Cut to $9 at Maxim Group; 'Buy' Maintained
-
Maxim Group Doesn't See Anything Nefarious at Anavex (AVXL)
-
Blue Sphere Completes Financing
-
Blue Sphere Completes Financing
-
Streetinsider.com's Hot Lunchtime Reads 12/23: (STEM) (ADMS) (LL) (CHK)
-
StemCells (STEM) PT Cut to $3 at Maxim Group
-
Maxim Group Reiterates Sell on Momenta (MNTA)
-
Athersys (ATHX) PT Cut to $5 at Maxim Group; 'Buy' Maintained
-
Caladrius Biosciences (CLBS) PT Cut to $4 at Maxim Group; 'Buy' Maintained


